|
1
|
Giannopoulou I, Mylona E, Kapranou A, et
al: The prognostic value of the topographic distribution of uPAR
expression in invasive breast carcinomas. Cancer Lett. 246:262–267.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Borstnar S, Sadikov A, Mozina B and Cufer
T: High levels of uPA and PAI-1 predict a good response to
anthracyclines. Breast Cancer Res Treat. 121:615–624. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jänicke F, Prechtl A, Thomssen C, et al;
German N0 Study Group. Randomized adjuvant chemotherapy trial in
high-risk, lymph node-negative breast cancer patients identified by
urokinase-type plasminogen activator and plasminogen activator
inhibitor type 1. J Natl Cancer Inst. 93:913–920. 2001.
|
|
4
|
Mani T, Wang F, Knabe WE, et al:
Small-molecule inhibition of the uPAR·uPA interaction: synthesis,
biochemical, cellular, in vivo pharmacokinetics and efficacy
studies in breast cancer metastasis. Bioorg Med Chem. 21:2145–2155.
2013.
|
|
5
|
Harbeck N, Kates RE, Gauger K, et al:
Urokinase-type plasminogen activator (uPA) and its inhibitor PAI-I:
novel tumor-derived factors with a high prognostic and predictive
impact in breast cancer. Thromb Haemost. 91:450–456.
2004.PubMed/NCBI
|
|
6
|
Efferth T, Dunstan H, Sauerbrey A, Miyachi
H and Chitambar CR: The anti-malarial artesunate is also active
against cancer. Int J Onco1. 18:767–773. 2001.
|
|
7
|
Gomme PT, McCann KB and Bertolini J:
Transferrin: structure, function and potential therapeutic actions.
Drug Discov Today. 10:267–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lu YY, Chen TS, Qu JL, Pan WL, Sun L and
Wei XB: Dihydroartemisinin (DHA) induces caspase-3-dependent
apoptosis in human lung adenocarcinoma ASTC-a-1 cells. J Biomed
Sci. 16:162009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakase I, Gallis B, Takatani-Nakase T, et
al: Transferrin receptor-dependent cytotoxicity of
artemisinin-transferrin conjugates on prostate cancer cells and
induction of apoptosis. Cancer Lett. 274:290–298. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakase I, Lai H, Singh NP and Sasaki T:
Anticancer properties of artemisinin derivatives and their targeted
delivery by transferrin conjugation. Int J Pharm. 354:28–33. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oh S, Kim BJ, Singh NP, Lai H and Sasaki
T: Synthesis and anti-cancer activity of covalent conjugates of
artemisinin and a transferrin-receptor targeting peptide. Cancer
Lett. 274:33–39. 2009. View Article : Google Scholar
|
|
12
|
Youns M, Efferth T, Reichling J,
Fellenberg K, Bauer A and Hoheisel JD: Gene expression profiling
identifies novel key players involved in the cytotoxic effect of
Artesunate on pancreatic cancer cells. Biochem Pharmacol.
78:273–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z, Yu Y, Ma J, et al: LyP-1
modification to enhance delivery of artemisinin or fluorescent
probe loaded polymeric micelles to highly metastatic tumor and its
lymphatics. Mol Pharm. 9:2646–2657. 2012. View Article : Google Scholar
|
|
14
|
Singh NP and Lai H: Selective toxicity of
dihydroartemisinin and holotransferrin toward human breast cancer
cells. Life Sci. 70:49–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lai H and Singh NP: Oral artemisinin
prevents and delays the development of
7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the
rat. Cancer Lett. 231:43–48. 2006.PubMed/NCBI
|
|
16
|
Li PC, Lam E, Roos WP, Zdzienicka MZ,
Kaina B and Efferth T: Artesunate derived from traditional Chinese
medicine induces DNA damage and repair. Cancer Res. 68:4347–4351.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hwang YP, Yun HJ, Kim HG, Han EH, Lee GW
and Jeong HG: Suppression of PMA-induced tumor cell invasion by
dihydroartemisinin via inhibition of PKCalpha/Raf/MAPKs and
NF-kappaB/AP-1-dependent mechanisms. Biochem Pharmacol.
79:1714–1726. 2010. View Article : Google Scholar
|
|
18
|
De Cremoux P, Grandin L, Diéras V, et al;
Breast Cancer Study Group of the Institut Curie. Urokinase-type
plasminogen activator and plasminogen-activator-inhibitor type 1
predict metastases in good prognosis breast cancer patients.
Anticancer Res. 29:1475–1482. 2009.PubMed/NCBI
|
|
19
|
Chen H, Sun B, Wang S, Pan S, Gao Y, Bai X
and Xue D: Growth inhibitory effects of dihydroartemisinin on
pancreatic cancer cells: involvement of cell cycle arrest and
inactivation of nuclear factor-kappaB. J Cancer Res Clin Oncol.
136:897–903. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan XJ, Plouet J, Lang JH, Wu M and Shen
K: Effects of dihydroartiminisin on proliferation and
phosphorylation of mitogen-activated protein kinase in epithelial
ovarian cancer cell lines. Zhonghua Fu Chan Ke Za Zhi. 43:662–665.
2008.(In Chinese).
|
